(R)-STU104 and Brefeldin-A Synergistically Enhance the Therapeutic Effect On IBD By Inhibiting the TAK1-MKK3-P38...

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Inflammatory Bowel Disease (IBD) presents significant patient and societal burdens.
• Current treatments for IBD are often suboptimal, with biological Tumor Necrosis Factor (TNF-α) inhibitors facing challenges like immunogenicity and cost.
• There is a need for novel therapeutic strategies targeting key inflammatory pathways in IBD.

Purpose of the Study:

• To investigate the therapeutic potential of Brefeldin A (BFA) and (R)-STU104 in treating IBD.
• To elucidate the mechanism of action involving the Transforming Growth Factor-β-Activated Kinase 1 (TAK1) - Mitogen-Activated Protein Kinase Kinase 3 (MKK3)-p38 signaling pathway.
• To evaluate the synergistic effects of combining BFA and (R)-STU104 for IBD treatment.

Main Methods:

• RAW264.7 macrophage cells were treated with BFA and (R)-STU104 to assess pathway inhibition via Western blotting and RT-qPCR.
• Dextran Sulfate Sodium (DSS)-induced IBD model in C57BL/6 mice was used to evaluate treatment efficacy.
• Disease Activity Index (DAI), colon length, and cytokine levels were monitored in vivo.

Main Results:

• Both BFA and (R)-STU104 demonstrated dose-dependent inhibition of the MKK3-p38 pathway and reduced TNF-α mRNA expression.
• Combination therapy significantly enhanced the inhibitory effect, reducing mRNA levels of TNF-α, Interleukin (IL)-1β, and IL-6.
• In the DSS-induced IBD model, the combination therapy alleviated disease symptoms, improved DAI scores, increased colon length, and reduced inflammatory cell infiltration.

Conclusions:

• BFA and (R)-STU104 exhibit synergistic anti-inflammatory effects by targeting the TAK1-MKK3-p38 pathway.
• The combination therapy represents a potential novel therapeutic strategy for Inflammatory Bowel Disease.
• Further research is warranted to confirm the clinical applicability of this combination therapy for IBD.